ser-155
ser-155: developed by 1 company · 1 clinical trial tracked.
ser-155 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ser-155 to MCRB; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ser-155 → MCRB affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Seres Therapeutics, Inc. (MCRB) | Phase 2 |
Clinical Trials (1)
A Single-Arm, Open-Label, Phase 1 Study to Assess Safety and Preliminary Efficacy of Cultivated Multi-Strain Live Bacterial Therapeutic SER-155 for First-Line Treatment of Immunotherapy-Related Enterocolitis
Primary endpoint: Proportion of participants with treatment-related adverse events of special interest
Interventionalopen15 targetStarted 2025-01Completion 2027-017 sites · United StatesMemorial Sloan Kettering Cancer Center
Frequently asked questions
Who is developing ser-155?
ser-155 is being developed by Seres Therapeutics, Inc..
How many clinical trials involve ser-155?
BioSniper tracks 1 clinical trial involving ser-155.